Literature DB >> 15280425

Release of a membrane-bound death domain by gamma-secretase processing of the p75NTR homolog NRADD.

Kavitha Gowrishankar1, Michael G Zeidler, Claudius Vincenz.   

Abstract

Neurotrophin receptor alike death domain protein (NRADD) is a death-receptor-like protein with a unique ectodomain and an intracellular domain homologous to p75(NTR). Expression of NRADD results in apoptosis, but only in certain cell types. This paper characterizes the expression and proteolytic processing of the mature 55 kDa glycoprotein. N-terminally truncated NRADD is processed by a gamma-secretase activity that requires presenilins and has the same susceptibility to gamma-secretase inhibitors as the secretion of amyloid beta (A beta). The ectodomain of endogenous NRADD is shed by activation of metalloproteinases. Inhibitor studies provide evidence that NRADD is cleaved in two steps typical of regulated intramembrane proteolysis (RIP). Inhibition of gamma-secretase abrogates both the production of the soluble intracellular domain of NRADD and the appearance of NRADD in subnuclear structures. Thus, solubilized death domains with close homology to p75(NTR) might have a nuclear function. Furthermore, presenilin deficiency leads to abnormally glycosylated NRADD and overexpression of presenilin 2 inhibits NRADD maturation, which is dependent on the putative active site residue D366 but not on gamma-secretase activity. Our results demonstrate that NRADD is an additional gamma-secretase substrate and suggest that drugs against Alzheimer's disease will need to target gamma-secretase in a substrate-specific manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280425     DOI: 10.1242/jcs.01263

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  11 in total

Review 1.  Substrate specificity of gamma-secretase and other intramembrane proteases.

Authors:  A J Beel; C R Sanders
Journal:  Cell Mol Life Sci       Date:  2008-05       Impact factor: 9.261

Review 2.  The Role of Presenilin in Protein Trafficking and Degradation-Implications for Metal Homeostasis.

Authors:  M A Greenough
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

Review 3.  Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.

Authors:  Geneviève Evin; Marijke Fleur Sernee; Colin L Masters
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  The many substrates of presenilin/γ-secretase.

Authors:  Annakaisa Haapasalo; Dora M Kovacs
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 5.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

6.  Ceramide signaling in cancer and stem cells.

Authors:  Erhard Bieberich
Journal:  Future Lipidol       Date:  2008-06

Review 7.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

8.  Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates.

Authors:  Andrew C Nyborg; Thomas B Ladd; Craig W Zwizinski; James J Lah; Todd E Golde
Journal:  Mol Neurodegener       Date:  2006-06-12       Impact factor: 14.195

9.  Pathological and physiological functions of presenilins.

Authors:  Kulandaivelu S Vetrivel; Yun-wu Zhang; Huaxi Xu; Gopal Thinakaran
Journal:  Mol Neurodegener       Date:  2006-06-12       Impact factor: 14.195

10.  Transcriptome analyses of 7-day-old zebrafish larvae possessing a familial Alzheimer's disease-like mutation in psen1 indicate effects on oxidative phosphorylation, ECM and MCM functions, and iron homeostasis.

Authors:  Yang Dong; Morgan Newman; Stephen M Pederson; Karissa Barthelson; Nhi Hin; Michael Lardelli
Journal:  BMC Genomics       Date:  2021-03-24       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.